Literature DB >> 10440915

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report.

J W Leach1, T Pham, D Diamandidis, J N George.   

Abstract

We present a case of a patient who developed all manifestations of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) acutely following treatment of cutaneous T-cell lymphoma (CTCL, Sezary syndrome) with deoxycoformycin (pentostatin). Symptoms and signs included severe thrombocytopenia and microangiopathic hemolytic anemia; hallucinations, confusion and disorientation; oliguric acute renal failure requiring hemodialysis; and fever. No other etiology for these symptoms and signs was present. Complete recovery followed treatment for one month with plasma exchange and glucocorticoids. During the succeeding 20 months she has remained well and her CTCL remains stable on no further treatment. This case and two previously published cases suggest that acute and severe TTP-HUS may be a dose-dependent toxicity of deoxycoformycin (pentostatin). Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440915     DOI: 10.1002/(sici)1096-8652(199908)61:4<268::aid-ajh9>3.0.co;2-o

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin.

Authors:  Jessica A Reese; Daniel W Bougie; Brian R Curtis; Deirdra R Terrell; Sara K Vesely; Richard H Aster; James N George
Journal:  Am J Hematol       Date:  2015-02-25       Impact factor: 10.047

2.  Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

Authors:  Simrit Parmar; Borje S Andersson; Daniel Couriel; Mark F Munsell; Marcelo Fernandez-Vina; Roy B Jones; Elizabeth J Shpall; Uday Popat; Paolo Anderlini; Sergio Giralt; Amin Alousi; Pedro Cano; Doyle Bosque; Chitra Hosing; Leandro de Padua Silva; Michael Westmoreland; J Kyle Wathen; Donald Berry; Richard E Champlin; Marcos J de Lima
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

3.  Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.

Authors:  Paolo Strati; Samih H Nasr; Nelson Leung; Curtis A Hanson; Kari G Chaffee; Susan M Schwager; Sara J Achenbach; Timothy G Call; Sameer A Parikh; Wei Ding; Neil E Kay; Tait D Shanafelt
Journal:  Haematologica       Date:  2015-06-18       Impact factor: 9.941

4.  Inhibition of adenosine deaminase (ADA)-mediated metabolism of cordycepin by natural substances.

Authors:  Gen Li; Izumi Nakagome; Shuichi Hirono; Tomoo Itoh; Ryoichi Fujiwara
Journal:  Pharmacol Res Perspect       Date:  2015-02-10

5.  An Update in Drug-Induced Thrombotic Microangiopathy.

Authors:  Thomas Chatzikonstantinou; Maria Gavriilaki; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  Front Med (Lausanne)       Date:  2020-05-22

6.  Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case.

Authors:  S Regragui; S Amelal; S Astati; M Zine; N Alami Drideb; A Al Bouzidi; N Messaoudi; M Benkirane; K Doghmi; M Mikdame
Journal:  Case Rep Hematol       Date:  2012-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.